After finishing at $2.53 in the prior trading day, Immuneering Corp (NASDAQ: IMRX) closed at $2.39, down -5.53%. In other words, the price has decreased by -$0.1400 from its previous closing price. On the day, 621862 shares were traded.
Ratios:
Our goal is to gain a better understanding of IMRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.35 and its Current Ratio is at 11.35. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 15, 2024, Reiterated its Buy rating but revised its target price to $15 from $20 previously.
Jefferies Downgraded its Buy to Hold on March 15, 2024, whereas the target price for the stock was revised from $16 to $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 22 ’24 when Feinberg Peter bought 25,000 shares for $2.55 per share. The transaction valued at 63,713 led to the insider holds 111,766 shares of the business.
Brakewood Harold Eugene bought 3,900 shares of IMRX for $10,015 on Mar 22 ’24. The Chief Business Officer now owns 3,900 shares after completing the transaction at $2.57 per share. On Mar 22 ’24, another insider, Schall Thomas J., who serves as the Director of the company, bought 2,900 shares for $2.55 each. As a result, the insider paid 7,385 and bolstered with 2,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMRX now has a Market Capitalization of 70.57M and an Enterprise Value of -10.63M. Its current Enterprise Value per Revenue stands at 191.91k whereas that against EBITDA is 0.18.
Stock Price History:
The Beta on a monthly basis for IMRX is -0.86, which has changed by -75.41% over the last 52 weeks, in comparison to a change of 29.19% over the same period for the S&P500. Over the past 52 weeks, IMRX has reached a high of $14.29, while it has fallen to a 52-week low of $1.90. The 50-Day Moving Average of the stock is 5.5307, while the 200-Day Moving Average is calculated to be 7.4386.
Shares Statistics:
The stock has traded on average 519.56K shares per day over the past 3-months and 2.96M shares per day over the last 10 days, according to various share statistics. A total of 29.27M shares are outstanding, with a floating share count of 21.03M. Insiders hold about 28.20% of the company’s shares, while institutions hold 55.17% stake in the company. Shares short for IMRX as of Feb 29, 2024 were 2.68M with a Short Ratio of 5.17, compared to 2.67M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.17% and a Short% of Float of 17.12%.
Earnings Estimates
Its stock is currently analyzed by 9 different market analysts. On average, analysts expect EPS of -$0.48 for the current quarter, with a high estimate of -$0.22 and a low estimate of -$0.59, while EPS last year was -$0.51. The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.23 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$0.93 and -$2.38 for the fiscal current year, implying an average EPS of -$1.88. EPS for the following year is -$1.92, with 8 analysts recommending between -$0.83 and -$2.62.
